Department of Animal Physiology, Institute of Biology and Ecology, Faculty of Science, Pavol Jozef Šafárik University in Košice, Šrobárová 2, 041 54 Košice, Slovak Republic.
Department of Medical Biology, Jessenius Faculty of Medicine, Comenius University in Bratislava, Malá Hora 4, 036 01 Martin, Slovak Republic.
Int J Mol Sci. 2018 Dec 6;19(12):3910. doi: 10.3390/ijms19123910.
Melatonin (N-acetyl-5-methoxytryptamine) is not only a pineal hormone, but also an ubiquitary molecule present in plants and part of our diet. Numerous preclinical and some clinical reports pointed to its multiple beneficial effects including oncostatic properties, and as such, it has become one of the most aspiring goals in cancer prevention/therapy. A link between cancer and inflammation and/or metabolic disorders has been well established and the therapy of these conditions with so-called pleiotropic drugs, which include non-steroidal anti-inflammatory drugs, statins and peroral antidiabetics, modulates a cancer risk too. Adjuvant therapy with melatonin may improve the oncostatic potential of these drugs. Results from preclinical studies are limited though support this hypothesis, which, however, remains to be verified by further research.
褪黑素（N-乙酰-5-甲氧基色胺）不仅是一种松果体激素，也是一种存在于植物和我们饮食中的普遍分子。大量的临床前和一些临床报告指出了它的多种有益作用，包括抗肿瘤特性，因此，它已成为癌症预防/治疗中最有前途的目标之一。癌症与炎症和/或代谢紊乱之间的联系已经得到充分证实，用所谓的多效性药物治疗这些疾病，包括非甾体抗炎药、他汀类药物和口服抗糖尿病药物，也可以调节癌症风险。用褪黑素进行辅助治疗可能会提高这些药物的抗肿瘤潜力。尽管临床前研究的结果支持这一假设，但仍需要进一步的研究来验证。
